Losartan increases NO release in afferent arterioles during regression of L-NAME-induced renal damage

American Journal of Physiology - Renal Physiology

Volumn 298, Issue 5, 2010, Pages

  Helle, Frank ^a,c,d   Iversen, Bjarne M ^c,d   Chatziantoniou, Christos ^a,b  

^a HÔPITAL TENON   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY OF BERGEN   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Angiotensin II; Endothelial dysfunction; Endothelin; Nitric oxide; Vascular remodeling

Indexed keywords

ANGIOTENSIN 1A RECEPTOR; CREATININE; ENDOTHELIN; HYDRALAZINE; LOSARTAN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOLE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CONVALESCENCE; DOSE RESPONSE; DRUG ANTAGONISM; ENZYME INHIBITION; HYPERTROPHY; KIDNEY FUNCTION; KIDNEY INJURY; MALE; MICROVASCULATURE; MUSCLE CONTRACTILITY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPRAGUE DAWLEY RAT; STIMULATION; VASOCONSTRICTION;

EID: 77951595799     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00056.2009     Document Type: Article

References (26)

1. Adamczak M, Gross ML, Krtil J, Koch A, Tyralla K, Amann K, Ritz E. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 14: 2833-2842, 2003. (Pubitemid 37305646)
2. Banting JD, Friberg P, Adams MA. Acute hypertension after nitric oxide synthase inhibition is mediated primarily by increased endothelin vasoconstriction. J Hypertens 14: 975-981, 1996. (Pubitemid 26306062)
3. Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 14: 1132-1144, 2003. (Pubitemid 36514656)
4. Boffa JJ, Tharaux PL, Dussaule JC, Chatziantoniou C. Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 37: 490-496, 2001. (Pubitemid 32199017)
5. 2 production in mouse cerebral arteries. Cardiovasc Res 73: 73-81, 2007.
6. Garland CJ, Plane F, Kemp BK, Cocks TM. Endothelium-dependent hyperpolarization: a role in the control of vascular tone. Trends Pharmacol Sci 16: 23-30, 1995.
7. Helle F, Hultstrom M, Skogstrand T, Palm F, Iversen BM. Angiotensin II-induced contraction is attenuated by nitric oxide in afferent arterioles from the nonclipped kidney in 2K1C. Am J Physiol Renal Physiol 296: F78-F86, 2009.
8. Helle F, Jouzel C, Chadjichristos C, Placier S, Flamant M, Guerrot D, Francois H, Dussaule JC, Chatziantoniou C. Improvement of renal hemodynamics during hypertension-induced chronic renal disease: role of EGF receptor antagonism. Am J Physiol Renal Physiol 297: F191-F199, 2009.
9. Hultstrom M, Helle F, Iversen BM. AT(1) receptor activation regulates the mRNA expression of CAT1, CAT2, arginase-1, and DDAH2 in preglomerular vessels from angiotensin II hypertensive rats. Am J Physiol Renal Physiol 297: F163-F168, 2009.
10. Kimura C, Oike M, Ohnaka K, Nose Y, Ito Y. Constitutive nitric oxide production in bovine aortic and brain microvascular endothelial cells: a comparative study. J Physiol 554: 721-730, 2004. (Pubitemid 38219886)
11. Kojima H, Nakatsubo N, Kikuchi K, Kawahara S, Kirino Y, Nagoshi H, Hirata Y, Nagano T. Detection and imaging of nitric oxide with novel fluorescent indicators: diaminofluoresceins. Anal Chem 70: 2446-2453, 1998. (Pubitemid 128501019)
12. Kramer C, Sunkomat J, Witte J, Luchtefeld M, Walden M, Schmidt B, Tsikas D, Boger RH, Forssmann WG, Drexler H, Schieffer B. Angiotensin II receptor-independent anti-inflammatory and anti-aggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 90: 770-776, 2002. (Pubitemid 34633892)
13. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001.
14. 2+ entry. Circ Res 87: 551-557, 2000.
15. Navar LG, Gilmore JP, Joyner WL, Steinhausen M, Edwards RM, Casellas D, Carmines PK, Zimmerhackl LB, Yokota SD. Direct assessment of renal microcirculatory dynamics. Fed Proc 45: 2851-2861, 1986.
16. Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD. Paracrine regulation of the renal microcirculation. Physiol Rev 76: 425-536, 1996.
17. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001.
18. Patzak A, Lai EY, Mrowka R, Steege A, Persson PB, Persson AE. AT1 receptors mediate angiotensin II-induced release of nitric oxide in afferent arterioles. Kidney Int 66: 1949-1958, 2004.
19. Pittner J, Wolgast M, Casellas D, Persson AE. Increased shear stressreleased NO and decreased endothelial calcium in rat isolated perfused juxtamedullary nephrons. Kidney Int 67: 227-236, 2005. (Pubitemid 40019244)
20. Placier S, Boffa JJ, Dussaule JC, Chatziantoniou C. Reversal of renal lesions following interruption of nitric oxide synthesis inhibition in transgenic mice. Nephrol Dial Transplant 21: 881-888, 2006.
21. Takenaka T, Hashimoto Y, Epstein M. Diminished acetylcholine-induced vasodilation in renal microvessels of cyclosporine-treated rats. J Am Soc Nephrol 3: 42-50, 1992.
22. Trottier G, Triggle CR, O'Neill SK, Loutzenhiser R. Cyclic GMP-dependent and cyclic GMP-independent actions of nitric oxide on the renal afferent arteriole. Br J Pharmacol 125: 563-569, 1998. (Pubitemid 28451496)
23. Uchihara M, Izumi N, Sato C, Marumo F. Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis. Hepatology 16: 95-99, 1992.
24. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ. Endothelin A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin B receptor blockade. Circulation 97: 752-756, 1998. (Pubitemid 28135337)
25. Watanabe T, Suzuki J, Yamawaki H, Sharma VK, Sheu SS, Berk BC. Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: angiotensin II type 1 receptor-independent effects of EXP3179. Circulation 112: 1798 - 1805, 2005.
26. Zhang R, Bai YG, Lin LJ, Bao JX, Zhang YY, Tang H, Cheng JH, Jia GL, Ren XL, Ma J. Blockade of AT1 receptor partially restores vasoreactivity, NOS expression, and superoxide levels in cerebral and carotid arteries of hindlimb unweighting rats. J Appl Physiol 106: 251-258, 2009.